Factories That Can't Pass WHO Inspection

Africa imports 99% of its vaccines and 70–90% of its pharmaceuticals. The continent has approximately 375 pharmaceutical manufacturers, but fewer than 10 have achieved WHO Prequalification (PQ) — the quality standard required for procurement by UN agencies and major donors. COVID-19 made this dependency existentially visible: African countries were last to receive vaccines despite carrying a significant disease burden. The African Union's Partnership for African Vaccine Manufacturing has set a target of 60% local vaccine production by 2040, but the gap between existing manufacturing capacity and PQ-level quality is vast. The barrier is not primarily financial or technological — manufacturing equipment can be purchased — but rather the quality management systems, regulatory infrastructure, and workforce skills that PQ demands.

Import dependency creates four compounding vulnerabilities. First, supply fragility: when global demand spikes (as in COVID-19), Africa is deprioritized by manufacturers serving wealthier markets. Second, cost inflation: importing finished products rather than manufacturing locally adds 30–50% to costs through logistics, tariffs, and foreign exchange exposure. Third, product mismatch: imported medicines may not include formulations appropriate for African disease profiles (pediatric formulations, heat-stable versions, fixed-dose combinations for African treatment guidelines). Fourth, sovereignty: no African country can implement a health policy that depends on products controlled by foreign manufacturers and foreign regulatory agencies.

Technology transfer agreements — where a multinational manufacturer licenses production to an African facility — have had limited success. The Aspen Pharmacare facility in South Africa produced COVID-19 vaccine doses under license from Johnson & Johnson but received no orders from African purchasers because COVAX and AVATT had already contracted with the original manufacturer. Egypt's VACSERA and Senegal's Institut Pasteur de Dakar have received investments for vaccine manufacturing but face multi-year timelines to achieve PQ. The core problem is that WHO PQ was designed for large-scale manufacturers in high-income countries; its quality documentation, validation, and inspection requirements assume institutional capacities (regulatory agencies with inspection expertise, reference standard libraries, environmental monitoring infrastructure) that most African countries lack. Meeting PQ is not just a manufacturer challenge — it requires a regulatory ecosystem that doesn't exist in most African countries.

The African Medicines Agency (AMA), whose treaty entered into force in 2021, could create a continental regulatory framework that builds toward PQ-equivalent standards through incremental steps — rather than requiring manufacturers to leap from minimal regulation to full PQ in one step. A stepwise manufacturing quality ladder — with procurement eligibility at each step, not just at the top — would allow manufacturers to build capacity and revenue simultaneously. The African Academy of Sciences has called for investment in the pharmaceutical sciences workforce (formulation scientists, quality assurance engineers, regulatory affairs specialists) as a prerequisite to manufacturing capacity, recognizing that equipment without expertise is an empty investment.

A regulatory analysis team could compare the WHO PQ requirements with the actual capabilities of 3–4 African manufacturers, identifying the specific quality system gaps (documentation, validation, environmental monitoring, stability testing) that prevent qualification and ranking them by difficulty and cost to close. A supply chain team could model the economics of regional pharmaceutical manufacturing hubs — where 3–5 countries share a manufacturing facility — to determine minimum production volumes for financial viability at different product mixes. A process engineering team could analyze which pharmaceutical manufacturing steps are most quality-sensitive and design simplified quality assurance protocols appropriate for lower-throughput African facilities.